Humacyte Receives Nasdaq Notice on Minimum Bid Requirement

Humacyte ( (HUMA) ) has provided an announcement.

On May 4, 2026, Humacyte disclosed that it received a notice from Nasdaq staff stating the company’s shares had closed below the $1.00 minimum bid requirement for 30 consecutive business days ended May 1, 2026, putting its Nasdaq Global Select Market listing at risk. Nasdaq has granted Humacyte until November 2, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, during which time HUMA shares will continue trading and the company plans to monitor its stock price and consider available options, though there is no assurance compliance will be restored.

The most recent analyst rating on (HUMA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.

Spark’s Take on HUMA Stock

According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.

The score is primarily constrained by weak financial performance—large losses, persistent cash burn, and high leverage with limited equity cushion. Technicals provide some support due to a positive short-term trend, but momentum looks stretched. Valuation is also pressured by negative earnings and no dividend yield data.

To see Spark’s full report on HUMA stock, click here.

More about Humacyte

Humacyte, Inc. operates in the biotechnology sector, focusing on the development of bioengineered human tissues and advanced regenerative medicine products for vascular and other critical applications. The company’s common stock trades on The Nasdaq Global Select Market under the ticker symbol HUMA, providing it access to public equity markets for funding its operations and growth.

Average Trading Volume: 6,988,216

Technical Sentiment Signal: Sell

Current Market Cap: $239.8M

Learn more about HUMA stock on TipRanks’ Stock Analysis page.